Affimed NV
NASDAQ:AFMD

Watchlist Manager
Affimed NV Logo
Affimed NV
NASDAQ:AFMD
Watchlist
Price: 0.1815 USD -34.95% Market Closed
Market Cap: 750k USD

Affimed NV
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Affimed NV
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Affimed NV
NASDAQ:AFMD
Cash from Operating Activities
-€76.9m
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
-26%
BioNTech SE
NASDAQ:BNTX
Cash from Operating Activities
€207.7m
CAGR 3-Years
-38%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Cash from Operating Activities
€101.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Cash from Operating Activities
-€176.4m
CAGR 3-Years
N/A
CAGR 5-Years
-41%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Cash from Operating Activities
€14.4m
CAGR 3-Years
-41%
CAGR 5-Years
N/A
CAGR 10-Years
0%
Formycon AG
XETRA:FYB
Cash from Operating Activities
-€23.2m
CAGR 3-Years
-20%
CAGR 5-Years
-73%
CAGR 10-Years
-93%
No Stocks Found

Affimed NV
Glance View

Market Cap
750k USD
Industry
Biotechnology

Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

AFMD Intrinsic Value
Not Available

See Also

What is Affimed NV's Cash from Operating Activities?
Cash from Operating Activities
-76.9m EUR

Based on the financial report for Sep 30, 2024, Affimed NV's Cash from Operating Activities amounts to -76.9m EUR.

What is Affimed NV's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-26%

Over the last year, the Cash from Operating Activities growth was 34%. The average annual Cash from Operating Activities growth rates for Affimed NV have been -21% over the past three years , and -26% over the past ten years .

Back to Top